



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#10/2  
3/10/01  
11-15-01  
**RECEIVED**  
NOV 13 2001  
TECH CENTER 1600/2900

Office Patent Application of:

Erwin SI *et al.*

Appl. No.: 09/523,102

Filed: March 10, 2000

For: Methods and Compositions for  
Treating and Preventing Retinal  
Neovascularization

Art Unit: 1651

Examiner: B. Ozga

Atty. Docket: 13587.286

**Response Under 35 U.S.C. 111(a) to the Office Action Dated October 25, 2001**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action dated October 25, 2001, (Paper No. 9), Applicants submit the following amendments and remarks.

**IN THE SPECIFICATION**

Please insert the following paragraph into the specification at page 1 line 3 following the title:

-- ~~This application is a continuation-in-part of U.S. patent application 09/127,920, filed August~~

~~3, 1998.~~

**Remarks**

This application has been amended to recite a priority claim under 35 U.S.C. 120 to U.S. application number 09/127,920. No new matter is added by this amendment. Following the entry of this amendment, claims 1 – 66 will be pending in the instant application. Claims 1- 42 are being examined on their merits, and claims 43-66 stand withdrawn from consideration pursuant to a restriction requirement under 35 U.S.C. 121.